Blisibimod
drugOn this page
Also known as A-623AMG 623AMG-623
Summary
Blisibimod (CHEMBL2107877) is a phase-3 clinical-stage unknown; indicated across 5 conditions including iga glomerulonephritis and systemic lupus erythematosus.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 5 conditions
- Clinical trials: 9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107877 |
| Name | Blisibimod |
| Type | Unknown |
| Max phase | 3 |
Also known as: A-623, AMG 623, AMG-623, Blisibimod, BLISIBIMOD
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| IgA glomerulonephritis | 3 | MONDO:0005342 | EFO:0004194 |
| systemic lupus erythematosus | 3 | MONDO:0007915 | MONDO:0007915 |
| autoimmune thrombocytopenic purpura | 2 | MONDO:0008558 | EFO:0007160 |
| granulomatosis with polyangiitis | 2 | MONDO:0012105 | EFO:0005297 |
| microscopic polyangiitis | 2 | MONDO:0019124 | EFO:1000784 |
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01395745 | PHASE3 | COMPLETED | CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus |
| NCT01609452 | PHASE2/PHASE3 | WITHDRAWN | MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP |
| NCT02052219 | PHASE3 | WITHDRAWN | BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy |
| NCT02062684 | PHASE2/PHASE3 | COMPLETED | BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration |
| NCT02074020 | PHASE3 | WITHDRAWN | CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis |
| NCT02514967 | PHASE3 | TERMINATED | CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis |
| NCT01162681 | PHASE2 | COMPLETED | PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus |
| NCT01305746 | PHASE2 | COMPLETED | A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 |
| NCT01598857 | PHASE2 | WITHDRAWN | BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).